TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04449692
Drug: Dasiglucagon
Normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdominal s.c. administration
Study: NCT00189826
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: immunosuppression
Study: NCT01364987
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT01999738
Drug: EC1456 and EC20
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging.
Study: NCT02094599
Drug: Dronabinol 10 mg
Normalized name: dronabinol 10 MG
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
Study: NCT02094599
Drug: Dronabinol 30 mg
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
Study: NCT01882361
Drug: injectable naltrexone
Normalized name: naltrexone Injection
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
Study: NCT00467649
Drug: pramlintide acetate (Symlin)
Normalized name: pramlintide acetate Pen Injector [Symlin]
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
Study: NCT00467649
Drug: rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])
Normalized name: insulin lispro Cartridge [Humalog]
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous injection, dosing based on titration guidelines
Study: NCT00467649
Drug: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection, dosing based on titration guidelines
Study: NCT01702506
Drug: dacomitinib+antacid
Normalized name: dacomitinib
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
Study: NCT01624194
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24IU BID (3 x 0.1 mL \[4IU\] sprays per nostril twice daily for 4-weeks.
Study: NCT02248376
Drug: Gel
Normalized name: Gel
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
Study: NCT01629849
Drug: BI 1021958 bid
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT01629849
Drug: BI 1021958 qd
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03165396
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is the most common clinical anesthetics.
Study: NCT03165396
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane is the most common clinical anesthetics.
Study: NCT00036114
Drug: aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00708396
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
Study: NCT00000889
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03459040
Drug: Alpha 1-Antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAT will be given either in the hospital or the outpatient clinic two times per week.
Study: NCT02765841
Drug: Lomitapide
Normalized name: Lomitapide
DrugBank: Lomitapide (DB08827)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00201799
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42
Study: NCT02493751
Drug: Avelumab (MSB0010718C)
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
Study: NCT02493751
Drug: Axitinib (AG-013736)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
Study: NCT03767569
Drug: Myo-inositol
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol and Folic acid daily
Study: NCT00003789
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via limb perfusion
Study: NCT04488822
Drug: Pexidartinib
Normalized name: PEXIDARTINIB
DrugBank: Pexidartinib (DB12978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
Study: NCT02772783
Drug: euglycemic insulin clamp
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
Study: NCT02772783
Drug: primed-variable insulin infusion
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are \> 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
Study: NCT00484354
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV bicarbonate given with amount based on patient weight
Study: NCT00886990
Drug: ritonavir-boosted PI-based second line treatments
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single PI boosted by low dose ritonavir
Study: NCT00886990
Drug: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
Study: NCT01525758
Drug: microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical number of tablets to active drug groups
Study: NCT03545464
Drug: Cortancyl Oral Tablet
Normalized name: Cortancyl
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortancyl oral Tablet 20 mg
Study: NCT03545464
Drug: Levocetirizine Oral Tablet
Normalized name: levocetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine Oral Tablet 5 mg
Study: NCT00986531
Drug: AZD8529
Normalized name: AZD8529
DrugBank: AZD8529 (DB16073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules by mouth for 3 days
Study: NCT00986531
Drug: Placebo to match AZD8529
DrugBank: AZD8529 (DB16073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules by mouth for 3 days
Study: NCT00232037
Drug: Tegaserod
Normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00094120
Drug: MSI-1256F (Squalamine Lactate)
Normalized name: morphine sulfate Oral Solution [MSIR]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03515187
Drug: 0.3% sodium hyaluronate ophthalmic solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one to two drops in eye, four times per day
Study: NCT03515187
Drug: 0.1% sodium bromide solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one to two drops in eye, twice per day
Study: NCT00995371
Drug: Epidural Steroid Injection
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
Study: NCT00124306
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
Study: NCT00403104
Drug: ONO-2506PO
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg QD / 18 months
Study: NCT00403104
Drug: ONO-2506PO
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg QD / 18 months
Study: NCT02134886
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01687673
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
Study: NCT04554862
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: magnesium sulfate will be added to the block
Study: NCT01687673
Drug: Sorafenib:
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
Study: NCT03476239
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator.
Study: NCT03476239
Drug: Dexamthasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
Study: NCT04554862
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac will be added to the block
Study: NCT02495363
Drug: Bupivacaine 0.25-0.5%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11
Study: NCT04226352
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan will be administered and its tolerability evaluated.
Study: NCT00904787
Drug: ENMD-2076
Normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, dose escalation, taken orally, daily in 28 day cycles
Study: NCT01656239
Drug: fedovapagon 1 mg
Normalized name: Fedovapagon
DrugBank: Fedovapagon (DB11734)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01656239
Drug: fedovapagon 2 mg
Normalized name: Fedovapagon
DrugBank: Fedovapagon (DB11734)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01656239
Drug: fedovapagon 4 mg
Normalized name: Fedovapagon
DrugBank: Fedovapagon (DB11734)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00986336
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
Study: NCT00986336
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-100 mg tablets twice daily for 2 weeks (400 mg/day)
Study: NCT00986336
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Twice daily, individualized dosing to stabilization at 1-6 mg/day.
Study: NCT00986336
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-25 mg tablets twice daily for 2 weeks (100 mg/day)
Study: NCT01583036
Drug: Digoxin Alone
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of digoxin 0.25mg
Study: NCT01583036
Drug: Digoxin + Retigabine
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
Study: NCT00337051
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia using Sevoflurane (inhalation) as hypnotic
Study: NCT00337051
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia with propofol TCI
Study: NCT03153852
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
Study: NCT02604784
Drug: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
Study: NCT05640375
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose, 1 mg/kg
Study: NCT03069131
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily administration of 1 tablet containing 550 mg of active rifaximin
Study: NCT02946996
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03717623
Drug: Posaconazole pharmacokinetics
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
Study: NCT02604784
Drug: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
Study: NCT02526225
Drug: Ginkgo diterpene lactone meglumine injection
Normalized name: citronellene lactone
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
Study: NCT02526225
Drug: Ginkgo diterpene lactone meglumine injection simulation
Normalized name: citronellene lactone
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
Study: NCT05082415
Drug: Brolucizumab
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants received brolucizumab injection during the index period
Study: NCT01067365
Drug: Androxal
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg once daily
Study: NCT01067365
Drug: Androxal
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg once daily
Study: NCT00909740
Drug: MEGF0444A
Normalized name: MEGF0444A
DrugBank: Parsatuzumab (DB14897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous escalating dose
Study: NCT04193774
Drug: artificial tears
Normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop of artificial tears in the other eye
Study: NCT03424122
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
Study: NCT03424122
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
Study: NCT03424122
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
Study: NCT03424122
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib administered orally once daily.
Study: NCT03461081
Drug: telmisartan/amlodipine and atorvastatin
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days